Improving Outcomes in Lethal Prostate Cancer Through Guideline-Concordant Use of Bone-Modifying Agents

Abstract

We used SEER-Medicare data to identify BMA underuse and overuse among prostate cancer patients, and then evaluated key patient, provider, and practice characteristics for association with underuse (approx. 68 percent receive BMAs appropriately) and overuse (approx. 1/3 non-candidate patients received BMA despite guidelines) [Aim 1]. We conducted in-depth interviews with prostate cancer clinicians to further understand barriers and facilitators to appropriate BMA use (analysis ongoing) [Aim 2A]. We will apply findings to refine a multi-pronged interventional strategy intended to reduce BMA underuse and overuse. Starting with a set of evidence-based healthcare interventions, we will use our findings to incorporate additional components tailored to correcting the identified barriers. We will pilot this intervention strategy within the MSK Alliance, a hybrid academic-community network of oncology providers in the Eastern US, to assess feasibility and efficacy [Aim 3].

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2022
Accession Number
AD1195573

Entities

People

  • Aaron Mitchell

Organizations

  • Sloan-Kettering Institute

Tags

DTIC Thesaurus Topics

  • Abstracts
  • Biomedical Research
  • Cancer
  • Cancer Screening
  • Clinical Trials
  • Data Analysis
  • Disparities
  • Distance Learning
  • Education
  • Health
  • Health Care
  • Health Services
  • Intervention
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Physicians
  • Professional Development
  • Prostate
  • Prostate Cancer
  • Public Health
  • Standards
  • Students
  • Training

Fields of Study

  • Medicine

Readers

  • Marine Ecological Systems Migration
  • Neurotrauma and Rehabilitation Medicine.
  • Women's Health and Cancer Risk Research: African American Women and Pregnancy Outcomes.